APO Research
Talk to an analyst

APO RESEARCH · REPORT

N-Acetylglutamate Synthetase Deficiency (NAGSD)

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Analysis and Forecast 2026-2032

29 December 2025199 pages

Choose your research edition.

Industry ResearchN-Acetylglutamate Synthetase Deficiency (NAGSD) Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal N-Acetylglutamate Synthetase Deficiency (NAGSD) Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal N-Acetylglutamate Synthetase Deficiency (NAGSD) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global N-Acetylglutamate Synthetase Deficiency (NAGSD) market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for N-Acetylglutamate Synthetase Deficiency (NAGSD) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for N-Acetylglutamate Synthetase Deficiency (NAGSD) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for N-Acetylglutamate Synthetase Deficiency (NAGSD) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for N-Acetylglutamate Synthetase Deficiency (NAGSD) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of N-Acetylglutamate Synthetase Deficiency (NAGSD) include Grand Pharmaceutical Group, Lee's Pharmaceuticals, Sovereign Medical, Sigmapharm Laboratories, Recordati Rare Diseases, Medunik, Immedica, Amgen and Acer Therapeutics, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for N-Acetylglutamate Synthetase Deficiency (NAGSD), market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of N-Acetylglutamate Synthetase Deficiency (NAGSD), also provides the revenue of main regions and countries. Of the upcoming market potential for N-Acetylglutamate Synthetase Deficiency (NAGSD), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the N-Acetylglutamate Synthetase Deficiency (NAGSD) revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global N-Acetylglutamate Synthetase Deficiency (NAGSD) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for N-Acetylglutamate Synthetase Deficiency (NAGSD) revenue, projected growth trends, production technology, application and end-user industry.

N-Acetylglutamate Synthetase Deficiency (NAGSD) Segment by Company

Grand Pharmaceutical Group

Lee's Pharmaceuticals

Sovereign Medical

Sigmapharm Laboratories

Recordati Rare Diseases

Medunik

Immedica

Amgen

Acer Therapeutics

N-Acetylglutamate Synthetase Deficiency (NAGSD) Segment by Type

Original Drug

Generic Drug

N-Acetylglutamate Synthetase Deficiency (NAGSD) Segment by Application

Adults

Children

N-Acetylglutamate Synthetase Deficiency (NAGSD) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global N-Acetylglutamate Synthetase Deficiency (NAGSD) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of N-Acetylglutamate Synthetase Deficiency (NAGSD) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of N-Acetylglutamate Synthetase Deficiency (NAGSD).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of N-Acetylglutamate Synthetase Deficiency (NAGSD) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of N-Acetylglutamate Synthetase Deficiency (NAGSD) company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, N-Acetylglutamate Synthetase Deficiency (NAGSD) revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Original Drug Major Player Table 3. Generic Drug Major Player Table 4. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Adults Major Player Table 6. Children Major Player Table 7. N-Acetylglutamate Synthetase Deficiency (NAGSD) Industry Trends Table 8. N-Acetylglutamate Synthetase Deficiency (NAGSD) Industry Drivers Table 9. N-Acetylglutamate Synthetase Deficiency (NAGSD) Industry Opportunities and Challenges Table 10. N-Acetylglutamate Synthetase Deficiency (NAGSD) Industry Restraints Table 11. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Region (2021-2026) & (US$ Million) Table 13. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Share by Region (2021-2026) Table 14. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Region (2027-2032) & (US$ Million) Table 15. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Share by Region (2027-2032) Table 16. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Players (US$ Million) & (2021-2026) Table 17. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Market Share by Players (2021-2026) Table 18. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Key Players Headquarters & Area Served Table 20. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Players, Product Type & Application Table 21. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Type (2021-2026) & (US$ Million) Table 26. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Type (2027-2032) & (US$ Million) Table 27. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Market Share by Type (2021-2026) Table 28. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Market Share by Type (2027-2032) Table 29. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Application (2021-2026) & (US$ Million) Table 31. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Application (2027-2032) & (US$ Million) Table 32. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Market Share by Application (2021-2026) Table 33. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Market Share by Application (2027-2032) Table 34. Grand Pharmaceutical Group Company Information Table 35. Grand Pharmaceutical Group Business Overview Table 36. Grand Pharmaceutical Group N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Grand Pharmaceutical Group N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio Table 38. Grand Pharmaceutical Group Recent Development Table 39. Lee's Pharmaceuticals Company Information Table 40. Lee's Pharmaceuticals Business Overview Table 41. Lee's Pharmaceuticals N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Lee's Pharmaceuticals N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio Table 43. Lee's Pharmaceuticals Recent Development Table 44. Sovereign Medical Company Information Table 45. Sovereign Medical Business Overview Table 46. Sovereign Medical N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Sovereign Medical N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio Table 48. Sovereign Medical Recent Development Table 49. Sigmapharm Laboratories Company Information Table 50. Sigmapharm Laboratories Business Overview Table 51. Sigmapharm Laboratories N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Sigmapharm Laboratories N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio Table 53. Sigmapharm Laboratories Recent Development Table 54. Recordati Rare Diseases Company Information Table 55. Recordati Rare Diseases Business Overview Table 56. Recordati Rare Diseases N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Recordati Rare Diseases N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio Table 58. Recordati Rare Diseases Recent Development Table 59. Medunik Company Information Table 60. Medunik Business Overview Table 61. Medunik N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Medunik N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio Table 63. Medunik Recent Development Table 64. Immedica Company Information Table 65. Immedica Business Overview Table 66. Immedica N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Immedica N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio Table 68. Immedica Recent Development Table 69. Amgen Company Information Table 70. Amgen Business Overview Table 71. Amgen N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Amgen N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio Table 73. Amgen Recent Development Table 74. Acer Therapeutics Company Information Table 75. Acer Therapeutics Business Overview Table 76. Acer Therapeutics N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Acer Therapeutics N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio Table 78. Acer Therapeutics Recent Development Table 79. North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Type (2021-2026) & (US$ Million) Table 80. North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Type (2027-2032) & (US$ Million) Table 81. North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Application (2021-2026) & (US$ Million) Table 82. North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Application (2027-2032) & (US$ Million) Table 83. North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 84. North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Country (2021-2026) & (US$ Million) Table 85. North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Country (US$ Million) & (2027-2032) Table 86. Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Type (2021-2026) & (US$ Million) Table 87. Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Type (2027-2032) & (US$ Million) Table 88. Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Application (2021-2026) & (US$ Million) Table 89. Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Application (2027-2032) & (US$ Million) Table 90. Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 91. Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Country (2021-2026) & (US$ Million) Table 92. Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Country (US$ Million) & (2027-2032) Table 93. China N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Type (2021-2026) & (US$ Million) Table 94. China N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Type (2027-2032) & (US$ Million) Table 95. China N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Application (2021-2026) & (US$ Million) Table 96. China N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Application (2027-2032) & (US$ Million) Table 97. Asia N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Type (2021-2026) & (US$ Million) Table 98. Asia N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Type (2027-2032) & (US$ Million) Table 99. Asia N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Application (2021-2026) & (US$ Million) Table 100. Asia N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Application (2027-2032) & (US$ Million) Table 101. Asia N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 102. Asia N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Region (US$ Million) & (2021-2026) Table 103. Asia N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Region (US$ Million) & (2027-2032) Table 104. SAMEA N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Type (2021-2026) & (US$ Million) Table 105. SAMEA N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Type (2027-2032) & (US$ Million) Table 106. SAMEA N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Application (2021-2026) & (US$ Million) Table 107. SAMEA N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Application (2027-2032) & (US$ Million) Table 108. SAMEA N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 109. SAMEA N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Country (2021-2026) & (US$ Million) Table 110. SAMEA N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Country (US$ Million) & (2027-2032) Table 111. Research Programs/Design for This Report Table 112. Authors List of This Report Table 113. Secondary Sources Table 114. Primary Sources List of Figures Figure 1. N-Acetylglutamate Synthetase Deficiency (NAGSD) Image Figure 2. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size Share 2021 VS 2025 VS 2032 Figure 4. Original Drug Image Figure 5. Generic Drug Image Figure 6. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size Share 2021 VS 2025 VS 2032 Figure 8. Adults Image Figure 9. Children Image Figure 10. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size (US$ Million) & (2021-2032) Figure 11. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Market Share by Type (2021-2032) Figure 18. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Market Share by Application (2021-2032) Figure 21. North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Share by Type (2021-2032) Figure 23. North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Share by Application (2021-2032) Figure 24. North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Share by Country (2021-2032) Figure 25. United States N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Share by Type (2021-2032) Figure 30. Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Share by Application (2021-2032) Figure 31. Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Share by Country (2021-2032) Figure 32. Germany N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Share by Type (2021-2032) Figure 42. China N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Share by Application (2021-2032) Figure 43. Asia N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Share by Type (2021-2032) Figure 45. Asia N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Share by Application (2021-2032) Figure 46. Asia N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Share by Region (2021-2032) Figure 47. Japan N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Share by Type (2021-2032) Figure 55. SAMEA N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Share by Application (2021-2032) Figure 56. SAMEA N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Share by Country (2021-2032) Figure 57. Brazil N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • Original Drug
  • Generic Drug
Applications
  • Adults
  • Children
Companies covered
  • Grand Pharmaceutical Group
  • Lee's Pharmaceuticals
  • Sovereign Medical
  • Sigmapharm Laboratories
  • Recordati Rare Diseases
  • Medunik
  • Immedica
  • Amgen
  • Acer Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 N-Acetylglutamate Synthetase Deficiency (NAGSD) Market by Type
  3. 1.2.1 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Original Drug
  5. 1.2.3 Generic Drug
  6. 1.3 N-Acetylglutamate Synthetase Deficiency (NAGSD) Market by Application
  7. 1.3.1 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Adults
  9. 1.3.3 Children
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Dynamics
  1. 2.1 N-Acetylglutamate Synthetase Deficiency (NAGSD) Industry Trends
  2. 2.2 N-Acetylglutamate Synthetase Deficiency (NAGSD) Industry Drivers
  3. 2.3 N-Acetylglutamate Synthetase Deficiency (NAGSD) Industry Opportunities and Challenges
  4. 2.4 N-Acetylglutamate Synthetase Deficiency (NAGSD) Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Perspective (2021-2032)
  2. 3.2 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Growth Trends by Region
  3. 3.2.1 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Region (2021-2026)
  5. 3.2.3 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Players
  2. 4.1.1 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Players (2021-2026)
  3. 4.1.2 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Key Players Headquarters & Area Served
  7. 4.4 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Players, Product Type & Application
  8. 4.5 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market CR5 and HHI
  11. 4.6.3 2025 N-Acetylglutamate Synthetase Deficiency (NAGSD) Tier 1, Tier 2, and Tier 3
5 N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Type
  1. 5.1 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Type (2021-2032)
  3. 5.3 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Market Share by Type (2021-2032)
6 N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Application
  1. 6.1 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Application (2021-2032)
  3. 6.3 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Grand Pharmaceutical Group
  2. 7.1.1 Grand Pharmaceutical Group Company Information
  3. 7.1.2 Grand Pharmaceutical Group Business Overview
  4. 7.1.3 Grand Pharmaceutical Group N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Grand Pharmaceutical Group N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio
  6. 7.1.5 Grand Pharmaceutical Group Recent Developments
  7. 7.2 Lee's Pharmaceuticals
  8. 7.2.1 Lee's Pharmaceuticals Company Information
  9. 7.2.2 Lee's Pharmaceuticals Business Overview
  10. 7.2.3 Lee's Pharmaceuticals N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Lee's Pharmaceuticals N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio
  12. 7.2.5 Lee's Pharmaceuticals Recent Developments
  13. 7.3 Sovereign Medical
  14. 7.3.1 Sovereign Medical Company Information
  15. 7.3.2 Sovereign Medical Business Overview
  16. 7.3.3 Sovereign Medical N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Sovereign Medical N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio
  18. 7.3.5 Sovereign Medical Recent Developments
  19. 7.4 Sigmapharm Laboratories
  20. 7.4.1 Sigmapharm Laboratories Company Information
  21. 7.4.2 Sigmapharm Laboratories Business Overview
  22. 7.4.3 Sigmapharm Laboratories N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Sigmapharm Laboratories N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio
  24. 7.4.5 Sigmapharm Laboratories Recent Developments
  25. 7.5 Recordati Rare Diseases
  26. 7.5.1 Recordati Rare Diseases Company Information
  27. 7.5.2 Recordati Rare Diseases Business Overview
  28. 7.5.3 Recordati Rare Diseases N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Recordati Rare Diseases N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio
  30. 7.5.5 Recordati Rare Diseases Recent Developments
  31. 7.6 Medunik
  32. 7.6.1 Medunik Company Information
  33. 7.6.2 Medunik Business Overview
  34. 7.6.3 Medunik N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Medunik N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio
  36. 7.6.5 Medunik Recent Developments
  37. 7.7 Immedica
  38. 7.7.1 Immedica Company Information
  39. 7.7.2 Immedica Business Overview
  40. 7.7.3 Immedica N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Immedica N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio
  42. 7.7.5 Immedica Recent Developments
  43. 7.8 Amgen
  44. 7.8.1 Amgen Company Information
  45. 7.8.2 Amgen Business Overview
  46. 7.8.3 Amgen N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Amgen N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio
  48. 7.8.5 Amgen Recent Developments
  49. 7.9 Acer Therapeutics
  50. 7.9.1 Acer Therapeutics Company Information
  51. 7.9.2 Acer Therapeutics Business Overview
  52. 7.9.3 Acer Therapeutics N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Acer Therapeutics N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio
  54. 7.9.5 Acer Therapeutics Recent Developments
8 North America
  1. 8.1 North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue (2021-2032)
  2. 8.2 North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Type (2021-2032)
  3. 8.2.1 North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Type (2021-2026)
  4. 8.2.2 North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Type (2027-2032)
  5. 8.3 North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Share by Type (2021-2032)
  6. 8.4 North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Application (2021-2032)
  7. 8.4.1 North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Application (2021-2026)
  8. 8.4.2 North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Application (2027-2032)
  9. 8.5 North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Share by Application (2021-2032)
  10. 8.6 North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Country
  11. 8.6.1 North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Country (2021-2026)
  13. 8.6.3 North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue (2021-2032)
  2. 9.2 Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Type (2021-2032)
  3. 9.2.1 Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Type (2021-2026)
  4. 9.2.2 Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Type (2027-2032)
  5. 9.3 Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Share by Type (2021-2032)
  6. 9.4 Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Application (2021-2032)
  7. 9.4.1 Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Application (2021-2026)
  8. 9.4.2 Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Application (2027-2032)
  9. 9.5 Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Share by Application (2021-2032)
  10. 9.6 Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Country
  11. 9.6.1 Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Country (2021-2026)
  13. 9.6.3 Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue (2021-2032)
  2. 10.2 China N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Type (2021-2032)
  3. 10.2.1 China N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Type (2021-2026)
  4. 10.2.2 China N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Type (2027-2032)
  5. 10.3 China N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Share by Type (2021-2032)
  6. 10.4 China N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Application (2021-2032)
  7. 10.4.1 China N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Application (2021-2026)
  8. 10.4.2 China N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Application (2027-2032)
  9. 10.5 China N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue (2021-2032)
  2. 11.2 Asia N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Type (2021-2032)
  3. 11.2.1 Asia N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Type (2021-2026)
  4. 11.2.2 Asia N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Type (2027-2032)
  5. 11.3 Asia N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Share by Type (2021-2032)
  6. 11.4 Asia N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Application (2021-2032)
  7. 11.4.1 Asia N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Application (2021-2026)
  8. 11.4.2 Asia N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Application (2027-2032)
  9. 11.5 Asia N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Share by Application (2021-2032)
  10. 11.6 Asia N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Country
  11. 11.6.1 Asia N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Country (2021-2026)
  13. 11.6.3 Asia N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue (2021-2032)
  2. 12.2 SAMEA N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Type (2027-2032)
  5. 12.3 SAMEA N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Application (2027-2032)
  9. 12.5 SAMEA N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Country
  11. 12.6.1 SAMEA N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst